8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSIONWashington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  February 28, 2008

BRUKER CORPORATION(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	000-30833 (Commission File Number)	04-3110160 (IRS Employer Identification No.)
40 Manning Road Billerica, MA 01821 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (978) 663-3660

Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the reporting obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act

o Soliciting material pursuant to Rule 14a-12 of the Exchange Act

o Pre-commencement communications pursuant to Rule 14d-2(b) Exchange Act

o Pre-commencement communications pursuant to Rule 13e-4(c) Exchange Act

Section 2 — Financial Information

Item 2.02.  Results of Operations and Financial Condition

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of  Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing of the company under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

On February 28, 2008, Bruker Corporation (formerly known as Bruker BioSciences Corporation) issued a press release announcing financial results as of and for the three and twelve months ended December 31, 2007.  A copy of the press release is attached hereto as Exhibit 99.1.

2

Section 9 — Financial Statements and Exhibits

Item 9.01.  Financial Statements and Exhibits.

(d)	Exhibits
	Number
		99.1	Press release dated February 28, 2008.

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BRUKER CORPORATION (Registrant)
Date: February 28, 2008	By:		/s/ Frank H. Laukien
		Frank H. Laukien, Ph.D. Chief Executive Officer and President

4

Exhibit Index

Exhibit Number	Exhibit Name	Location
99.1	Press release dated February 28, 2008.	Furnished herewith*

*Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

5

EX-99.1

Bruker Corporation Reports Record Revenues and Earnings for the Fourth Quarter and Full Year 2007

Full Year 2007 Revenue Increased 19% (after Currency Adjustments) to $547.6 Million, and Full Year 2007 Net Income Grew 70% to $31.5 Million

BILLERICA, Mass., February 28, 2008 (BUSINESS WIRE)  —  Bruker Corporation (NASDAQ: BRKR) today reported financial results for the fourth quarter and full year ended December 31, 2007.  The financial information included herein does not include the results of the Bruker BioSpin Group, which was acquired on February 26, 2008, but only the financial results of the standalone Bruker BioSciences Corporation, as it legally existed on December 31, 2007.

On February 26, 2008, Bruker BioSciences Corporation closed its acquisition of the Bruker BioSpin Group, and renamed itself Bruker Corporation.  Under US GAAP, this transaction will be accounted for as an acquisition of businesses under common control, and as a result all one-time transaction costs are expensed in the period in which they are incurred, rather than being added to goodwill.  In addition, after the closing of the transaction all historical consolidated balance sheets, statements of operations, statements of cash flows and notes to the consolidated financial statements in future filings with the Securities and Exchange Commission will be restated by combining the historical consolidated financial statements of Bruker BioSciences Corporation with those of the Bruker BioSpin Group.  The Bruker BioSpin Group standalone financial results, as well as combined financial results for Bruker Corporation, are expected to be released in mid-March 2008.  At that time, the newly combined Company will also provide an update on its financial goals for the year 2008.

Financial Results of Bruker BioSciences (excluding the Bruker BioSpin Group)

For the fourth quarter of 2007, revenue increased by 35% to $183.7 million, compared to revenue of $135.6 million in the fourth quarter of 2006.  Excluding the effects of foreign currency translation, fourth quarter 2007 revenue increased organically by 26% year-over-year.

Net income in the fourth quarter of 2007 increased 44% to $14.0 million, or $0.13 per diluted share, compared to net income of $9.7 million, or $0.09 per diluted share, in the fourth quarter of 2006.  Included in GAAP net income for the fourth quarter of 2007 were after-tax charges of $4.3 million, or $0.04 per diluted share, for expenses related to the acquisition of the Bruker BioSpin Group.

For the full year 2007, revenue increased by 26% to $547.6 million, compared to revenue of $435.8 million for the full year 2006.  Excluding the effects of foreign currency translation, full year 2007 revenue increased by 19% year-over-year, including 17% organic growth and 2% growth from acquisitions.

Net income for the full year 2007 increased 70% to $31.5 million, or $0.30 per diluted share, compared to net income of $18.5 million, or $0.18 per diluted share, during the full year 2006.  Included in GAAP net income for the full year 2007 were after-tax charges of $4.7 million, or $0.04 per diluted share, for expenses related to the acquisition of the Bruker BioSpin Group.  For comparison, included in GAAP net income for the year 2006 were after-tax charges of $5.0 million, or $0.05 per diluted share, for expenses related to the acquisition of Bruker Optics.

During the fourth quarter of 2007, cash flow from operations was $36.4 million and free cash flow, defined as operating cash flow less capital expenditures, was $34.3 million.  During the full year 2007, cash flow from operations was $26.3 million and free cash flow was $10.8 million.  As of December 31, 2007, the Company had $72.9 million in cash and cash equivalents, and $38.1 million in outstanding debt.

Commenting on the Company’s financial performance, Frank Laukien, President and CEO, said: “We had an outstanding fourth quarter, and we are very pleased that during 2007 we have achieved excellent top-line growth, with all three operating divisions delivering currency-adjusted double digit growth year-over-year.  Even more importantly, our rapid growth, our continued operating margin expansion and our decreasing effective tax rate contributed to significantly improved bottom-line performance year-over-year, as well as to solid operating and free cash flow.”

He continued: “Bruker BioSciences has made very good progress over the last three years.  We will continue to strive for fast growth and further margin improvements in order to reach industry-standard profitability, and we will put a significant focus on balance sheet management and cash flow generation.  We are optimistic that the renamed Bruker Corporation, which as of two days ago includes the Bruker BioSpin Group, is well positioned to serve our customers and markets with high-performance products and solutions.  Despite the uncertainty in the macro-economic outlook, at this point the Company expects significant further financial improvements in the year 2008.”

EARNINGS CONFERENCE CALL

Bruker Corporation will host an operator-assisted earnings conference call at 9 a.m. Eastern Time on Thursday, February 28, 2008.  To listen to the webcast, investors can go to www.bruker-biosciences.com and click on the live web broadcast symbol.  The webcast will be available through the Company web site for 30 days.  Investors can also listen and participate on the telephone in the US and Canada by calling 888-339-2688, or 617-847-3007 outside the US and Canada.  Investors should refer to the Bruker Corporation Quarterly Earnings Call.  A telephone replay of the conference call will be available one hour after the conference call by dialing 888-286-8010 in the US and Canada, or 617-801-6888 outside the US and Canada, and then entering replay pass code 11927586.

ABOUT BRUKER CORPORATION

As of February 26, 2008, the renamed Bruker Corporation (NASDAQ: BRKR) has become the parent company of the entire Bruker group of companies.  After the closing of the acquisition of the Bruker BioSpin Group, Bruker Corporation now operates in two segments, the life science

and analytical (LSA) systems segment, and the international advanced superconductor (IAS) segment.  For more information, please visit www.bruker-biosciences.com

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, intellectual property rights, litigation, and exposure to foreign currency fluctuations. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2006, our most recent quarterly reports on Form 10-Q and  our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements other than as required by law.

Bruker Corporation (excluding the Bruker BioSpin Group)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

	Three Months Ended December 31,						Twelve Months Ended December 31,
	2007			2006			2007			2006
Product revenue	$	164,910		$	120,444		$	482,153		$	384,548
Service revenue	18,384			14,960			64,553			49,930
Other revenue	449			221			870			1,356
Total revenue	183,743			135,625			547,576			435,834
Cost of product revenue	85,605			63,214			252,130			206,628
Cost of service revenue	12,492			9,239			42,308			29,872
Total cost of revenue	98,097			72,453			294,438			236,500
Gross profit margin	85,646			63,172			253,138			199,334
Operating Expenses:
Sales and marketing	31,074			25,212			105,983			84,007
General and administrative	10,392			8,663			34,058			28,982
Research and development	16,164			13,464			58,466			49,959
Acquisition related charges	4,294			(105		)	4,664			5,724
Total operating expenses	61,924			47,234			203,171			168,672
Operating income	23,722			15,938			49,967			30,662
Interest and other income (expense), net	(530		)	236			(1,355		)	3,758
Income before income tax provision and minority interest in consolidated subsidiaries	23,192			16,174			48,612			34,420
Income tax provision	9,129			6,533			16,784			15,931
Income before minority interest in consolidated subsidiaries	14,063			9,641			31,828			18,489
Minority interest in consolidated subsidiaries	44			(67		)	299			8
Net income	$	14,019		$	9,708		$	31,529		$	18,481
Net income per share:
Basic	$	0.13		$	0.10		$	0.30		$	0.18
Diluted	$	0.13		$	0.09		$	0.30		$	0.18
Weighted average shares outstanding:
Basic	104,508			101,501			103,702			101,512
Diluted	107,180			103,370			106,769			102,561

Bruker Corporation (excluding the Bruker BioSpin Group)

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

	December 31,		December 31,
	2007		2006
ASSETS
Current assets:
Cash and short-term investments	$	72,876	$	52,147
Accounts receivable, net	114,938		79,604
Due from affiliated companies	7,203		9,028
Inventories	171,332		134,504
Other current assets	29,281		19,461
Total current assets	395,630		294,744
Property and equipment, net	103,100		90,349
Intangible and other assets	54,483		48,094
Total assets	$	553,213	$	433,187
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Short-term borrowings	$	31,716	$	21,857
Accounts payable	32,584		23,102
Due to affiliated companies	8,326		5,901
Other current liabilities	180,327		144,268
Total current liabilities	252,953		195,128
Long-term debt	6,394		22,863
Other long-term liabilities	34,702		23,491
Minority interest in subsidiaries	505		239
Total shareholders’ equity	258,659		191,466
Total liabilities and shareholders’ equity	$	553,213	$	433,187

FOR FURTHER INFORMATION:	Michael Willett, Investor Relations Officer
	Tel:  +1 (978) 663-3660, ext. 1411
	Email:  Michael.Willett@Bruker.com